Merck & Co., Inc. stock (US58933Y1055): Latest developments and business overview

Merck & Co., Inc., a global leader in pharmaceuticals, maintains its position as a key player for US investors through its robust oncology portfolio and vaccine offerings. The company reported strong performance in its latest quarterly results, with Keytruda sales highlighting ongoing demand in the US market.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

Merck & Co., Inc.: core business model

Merck & Co., Inc. operates as a research-driven pharmaceutical company focused on discovering, developing, and marketing innovative health solutions. Its business model centers on a diversified portfolio spanning oncology, vaccines, hospital acute care, and animal health. The company invests heavily in R&D, with expenditures supporting a pipeline of over 80 programs as detailed in its 2025 annual report.

Merck generates revenue primarily through patented blockbuster drugs, licensing agreements, and partnerships. Keytruda, its anti-PD-1 therapy, remains the cornerstone, approved for multiple cancer indications and contributing significantly to US sales. The model emphasizes lifecycle management, extending product exclusivity through new formulations and indications.

Main revenue and product drivers for Merck & Co., Inc.

Oncology accounts for the largest revenue share, led by Keytruda, which posted global sales of $25 billion in 2024, per the company's Q4 2024 earnings release as of Feb 2025. Vaccines like Gardasil drive growth in preventive care, with strong uptake in the US market amid rising HPV awareness.

Animal health, under the MSD brand outside the US, provides stable cash flows from products like Bravecto for pets. Recent expansions into cardiovascular and immunology bolster diversification, reducing reliance on any single therapy.

Industry trends and competitive position

The pharmaceutical sector faces patent cliffs and biosimilar competition, yet Merck's position remains strong with Keytruda's dominance in immuno-oncology. US investors benefit from the company's exposure to the $500 billion+ domestic market, where Medicare and private payers influence pricing dynamics, according to IQVIA data as of 2025.

Merck competes with Pfizer, Bristol Myers Squibb, and Roche, differentiating through its R&D scale and strategic acquisitions like Acceleron Pharma, enhancing its rare disease portfolio.

Why Merck & Co., Inc. matters for US investors

Listed on the NYSE under MRK, Merck offers US investors direct access to a blue-chip pharma stock with substantial S&P 500 weighting. Its products address critical US health needs, from cancer care to vaccines, tying performance to American healthcare spending trends.

The stock traded at approximately $110 USD on NYSE as of early 2026 market data from official exchange sources, reflecting resilience amid sector volatility.

Conclusion

Merck & Co., Inc. stands as a pillar in the US pharmaceutical landscape, with its oncology and vaccine franchises fueling sustained growth. Investors monitor pipeline progress and patent dynamics closely. The company's strategic focus positions it well amid evolving healthcare demands.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.